We describe here a case of a 33-year-old man who had lichen amyloidosus associated with Kimura’s disease. In this case, treatment with cyclosporine dramatically improved the lesions of both Kimura’s disease and lichen amyloidosus. Although Kimura’s disease and lichen amyloidosus are both rare distinct entities, to our knowledge, 11 cases of association of Kimura’s disease and lichen amyloidosus have been described previously.

Keywords:
Kimura’s disease, Lichen amyloidosus, Cyclosporine
1.
Danno K, Horio T, Miyachi Y, Hayakawa M, Takatsuki K: Coexistence of Kimura’s disease and lichen amyloidosus in three patients. Arch Dermatol 1982;118–976–980.
2.
Sakuma M, Okuyama S, Suzuki M, Baba T, Takahashi H, Yaoita H, Uyeno K: Kimura’s disease accompanied with lichen amyloidosus (in Japanese). Nippon Hifuka Gakkai Zasshi 1984;94:225–233.
3.
Mikami K, Nakayama K, Kusumoto K, Nakamura S: Kimura’s disease accompanied with lichen amyloidosus (abstract, in Japanese). Nippon Hifuka Gakkai Zasshi 1989;99:946.
4.
Nishimoto K, Nishimoto M, Yamamoto S, Nakajima K: Kimura’s disease with peculiar clinical course (in Japanese). Rinsho Hihuka 1990;44:1185–1188.
5.
Matsushita S, Fujiwara M, Mitsuya H, Takatsuki K, Hirajima M: Kimura’s disease accompanied with lichen amyloidosus (abstract, in Japanese). Nippon Naika Gakkai Zasshi 1983;72:832.
6.
Weyers W, Weyers I, Bonczkowitz M, Diaz-Cascajo C, Schill WB: Lichen amyloidosus: A consequence of scratching. J Am Acad Dermatol 1997;37:923–928.
7.
Shanon J: Cutaneous amyloidosis associated with atopic disorders. Dermatologica 1970;141:297–302.
8.
Nyrop M: Kimura’s disease: Case report and brief review of literature. J Laryngol Otol 1994;108:1005–1007.
9.
Daaleman T, Woodroof J: Kimura’s disease presenting as subcutaneous facial plaque in an African American. Cutis 2000;66:201–204.
10.
Senel MF, Van Buren CT, Etheridge WB, Barcenas C, Jammal C, Kahan BD: Effects of cyclosporine, azathioprine and prednisone on Kimura’s disease and focal segmental glomerulosclerosis in renal transplant patients. Clin Nephrol 1996;45:18–21.
11.
Katagiri K, Itami S, Hatano Y, Yamaguchi T, Takayasu S: In vivo expression of IL-4, IL-5, IL-13 and IFN-gamma mRNAs in peripheral blood mononuclear cells and effect of cyclosporine A in a patient with Kimura’s disease. Br J Dermatol 1997;137:972–977.
12.
Kaneko K, Aoki M, Hattori S, Sato M, Kawana S: Successful treatment of Kimura’s disease with cyclosporine. J Am Acad Dermatol 1999;41:893–894.
13.
Breathnach SM: Amyloid and amyloidosis. J Am Acad Dermatol 1988;18:1–16.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.